GSK at ASH 2022
GSK is presenting new data exploring the potential of its pipeline and development portfolio to help address gaps in the current landscape of difficult-to-treat blood cancers.
At ASH, the presentations will focus on long-term analyses from pivotal studies that will further the understanding of the efficacy and tolerability of therapies. Additionally, through collaborative studies with renowned hematologists and institutions, data will demonstrate how combinations of therapies in different lines of treatment may improve outcomes for patients. This research further emphasizes the importance of the Janus kinase (JAK)1, JAK2 and activin A receptor, type I (ACVR1) signaling pathways, as well as advances the understanding of targeting b-cell maturation antigen (BCMA).
GSK aims to get ahead of blood cancers through its commitment to address the significant medical needs of patients. With expansion of the company’s investigational blood cancer pipeline, as well as robust research programs for therapies in its portfolio, the Company is working towards maximizing patient survival through the development of transformational medicines.
At GSK, we unite science, technology and talent to get ahead of cancer together. If you are a healthcare professional, you can learn more about our marketed products by selecting your market and the specific GSKPro website on our worldwide directory.
Patient stories
Supporting the myelofibrosis community
In August 2022, we joined the “Sole 2 Soul for MPN” hike in Waterton Lakes National Park, Canada. The five-day trek, which ended in a grand finale climb within the Canadian Rockies, is a collaboration between the Canadian MPN Research Foundation, the MPN Research Foundation and CURE Media Group and provided participants an opportunity to raise funds and awareness for MPNs, including myelofibrosis.
